Company / FCF Margin
Taysha Gene Therapies, Inc. FCF Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-960.1%
FY2025
5-year range
-5289.6% / -497.6%
FY2022-FY2025
Trend
-92.9%
vs FY2024
Sector context
#121 of 134
Health Care
What the data says
Among 134 Health Care companies, Taysha Gene Therapies, Inc. is in the bottom 10% for fcf margin. Improved from -4356.9% to -960.1% over the past 2 years.
Based on SEC 10-K filings.
-960.1% in FY2025 with a 3-year CAGR of +4329.5%.
Improved from -4356.9% to -960.1% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +4329.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 134This company -960.1% Sector average -637.8%
▼
-50.5% below sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 92.9% year-over-year.
- Currently 322.3pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -960.1% | -92.9% |
| FY2024 | -497.6% | +88.6% |
| FY2023 | -4356.9% | +17.6% |
| FY2022 | -5289.6% | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026